【摘要】 目的 :探讨金属硫蛋白 (MT)在浸润性乳腺导管癌中的表达及其临床意义。方法 :常规免疫组化LAB法检测了 96例浸润性乳腺导管癌术后标本中MT的表达情况。结果 :浸润性乳腺导管癌标本的MT表达率为 5 2 1% (5 0 / 96 ) ,在大多数阳性病例中胞浆、胞核均着色。MT表达与乳腺癌的核分级有关 (P <0 0 1) ;MT表达阳性者和阴性者相比预后大多较差 (P <0 0 1)。结论 :MT表达可预测乳腺癌的预后 ,MT有可能作为又一个增殖旺盛、侵袭性强的肿瘤标志物更多还原

【Abstract】 AIM:To asses the presence and clinical significance of metallothionein,(MT) in primary invasive ductal carcinoma of the breast. METHOD: 96 cases of routinely fixed and paraffin-embedded primary breast carcinomas were investigated with the labelled avidin biotin immunohistochemical method. RESULTS: The positive staining for MT observed was 52.1% (50/96). In most cases both nuclear and cytoplasmic staining was seen. A statistically association was found between MT positive staining and nuclear grade( P< 0.01).MT positive cases had a significantly poorer prognosis when compared with the MT negative cases ( P< 0.01). CONCLUSION:These results indicated that overexpression of MT may be of some prognostic value for primary invasive ductal carcinoma of the breast and is possibly a biomarker of more aggressive and proliferating carcinoma cells.更多还原